Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Código da empresaAVXL
Nome da EmpresaAnavex Life Sciences Corp
Data de listagemApr 13, 2006
Fundado em2004
CEODr. Christopher U. Missling, Ph.D.
Número de funcionários42
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 13
Endereço630 5Th Avenue
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10111
Telefone18446893939
Sitehttps://www.anavex.com
Código da empresaAVXL
Data de listagemApr 13, 2006
Fundado em2004
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados